UNCOVER TRK FUSION CANCER WITH VARIOUS TESTING METHODOLOGIES

Actionable alterations may be present in many tumors^1,2

30% to 49% of patients who undergo tumor genomic profiling may have an actionable Actionable means that the alteration is associated with an approved or investigational therapy. ² alteration^1,2

LEARN MORE FROM EXPERTS ABOUT NTRK AND TESTING CONSIDERATIONS

Specific tests can uncover TRK fusion cancer

Next-generation sequencing (NGS)^3,6,9,10

Pan-TRK immunohistochemistry assays (IHC)¹¹

DNA fluorescence in situ hybridization (FISH)^9,10,12

Reverse transcription polymerase chain reaction (RT-PCR)^9,13

ADD NTRK GENE FUSION TO YOUR TESTING PROTOCOL

UNCOVER TRK FUSION CANCER WITH VARIOUS TESTING METHODOLOGIES

* TRK, tropomyosin receptor kinase.

^a NTRK, neurotrophic receptor tyrosine kinase.

References: 1. Massard C, Michiels S, Ferte C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586-595. 2. Boland GM, Piha-Paul SA, Subbiah V, et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015;6(24):20099-20110. 3. Vaishnavi A, Le AT, Doebele RC. Cancer Discov. 2015;5(1):25-34. 4. Okimoto RA, Bivona TG. Tracking down response and resistance to TRK inhibitors. Cancer Discov. 2016;6(1):14-16. 5. Amatu A, Sartore-Bianchi A, Siena S. ESMO Open. 2016;1(2):e000023. 6. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 2015;7:129. doi:10.1186/s13073-015-0252-1. 7. Lange AM, Lo H-W. Inhibiting TRK proteins in clinical cancer therapy. Cancers. 2018;10(4):E105. doi:10.3390/cancers10040105. 8. Stransky N, Cerami E, Schalm S, Lim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846. doi:10.1038/ncomms5846. 9. Abel HJ, Al-Kateb H, Cottrell CE, et al. Detection of gene rearrangements in targeted clinical next-generation sequencing. J Mol Diagn. 2014;16(4):405-417. 10. Rogers T-M, Arnau GM, Ryland GL, et al. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep. 2017;7:42259. doi:10.1038/srep42259. 11. Hechtman JF, Benayed R, Hyman DM, et al. Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547-1551. 12. Yan L, Zhang W. Precision medicine becomes reality—tumor type-agnostic therapy. Cancer Commun. 2018;38(1):6. doi:10.1186/s40880-018-0274-3. 13. Vendrell JA, Taviaux S, Béganton B, et al. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep. 2017;7(1):12510. doi:10.1038/s41598-017-12679-8.

THERE’S MORE TO SOME CANCERS THAN MEETS THE EYE

What's Driving The Tumor?

Actionable alterations may be present in many tumors^1,2

30% to 49% of patients who undergo tumor genomic profiling may have an actionable Actionable means that the alteration is associated with an approved or investigational therapy. ² alteration^1,2

Specific tests can uncover TRK fusion cancer

ADD NTRK GENE FUSION TO YOUR TESTING PROTOCOL

Share this page

THERE’S MORE TO SOME CANCERS THAN MEETS THE EYE

What's Driving The Tumor?

Actionable alterations may be present in many tumors1,2

30% to 49% of patients who undergo tumor genomic profiling may have an actionable Actionable means that the alteration is associated with an approved or investigational therapy. 2 alteration1,2

Specific tests can uncover TRK fusion cancer

ADD NTRK GENE FUSION TO YOUR TESTING PROTOCOL

Actionable alterations may be present in many tumors^1,2

30% to 49% of patients who undergo tumor genomic profiling may have an actionable Actionable means that the alteration is associated with an approved or investigational therapy. ² alteration^1,2